Pharma BD Deal Intelligence
Not actually an acquisition — a $120M licensing deal for two pain-management products that both flopped and was unwound within 4 years
Full analysis, sources & comparables →Endo received an exclusive license to US and Canadian rights for DEPOMORPHINE and Propofol IDD-D. SkyePharma will receive a US$25 million upfront payment plus…
DepoDur is an extended-release liposome injection of morphine sulfate FDA approved May 18, 2004 — the first single-dose extended-release epidural morphine…
Endo and SkyePharma agreed to terminate joint North American development of Propofol IDD-D after Phase II completion in 2004, ending the second leg of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Endo paid $120M for rights to Depomorphine and Propofol IDD-D plus options on additional SkyePharma assets. Sources: Endo Pharmaceuticals 10-K (year 2003), industry coverage.
Not actually an acquisition — a $120M licensing deal for two pain-management products that both flopped and was unwound within 4 years
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Pharmaceuticals Inc. / SkyePharma plc (this deal) | 2003 | $120M | 17 |
| Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation | 2000 | $250M | 34 |
| Endo Pharmaceuticals Inc. / Indevus Pharmaceuticals, Inc. | 2009 | $370M | 33 |
| Endo Pharmaceuticals Inc. / HealthTronics, Inc. | 2010 | $223M | 17 |
| Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals | 2010 | $1.2B | 17 |
| Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc. | 2011 | $2.9B | 13 |
| Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co. | 2010 | $144M | 13 |
← Browse all deals · How we score deals
More: 2003 deals · Endo Pharmaceuticals Inc. deals · Other deals